BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...a CD37-targeted radionuclide therapy to treat lymphoma (see “Radiotherapy Blasts Forward” ). Bone healing company Bioventus Inc....
...Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen Pharma Ltd. Iveric bio Inc. Nordic Nanovector ASA Viracta Therapeutics Inc. Bioventus Inc....
BioCentury | Apr 30, 2019
Distillery Therapeutics

BMP2/BMP6/activin A-based chimera for bone repair

...chimera plus the granule-COL1 matrix increased bone remodeling compared with pretreatment baselines. Next steps by Bioventus Inc....
...repair. TARGET/MARKER/PATHWAY: Bone morphogenetic protein 2 (BMP2); BMP6; activin A LICENSING STATUS: Patented; licensed to Bioventus Inc....
...published online Apr. 24, 2019 doi:10.1126/scitranslmed.aar4953 CONTACT: Howard J. Seeherman, Bioventus Inc., Durham, N.C. email: hseeherman@gmail.com Claire Quang Bioventus Inc. Activin...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...He was CFO and head of business development at AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX). Orthobiologics company Bioventus Inc....
BioCentury | May 2, 2017
Company News

Management tracks

...15. He will succeed Edward Borkowski, who is leaving the company. Price was CFO of Bioventus Inc....
BioCentury | Dec 30, 2016
Company News

Bioventus, Galderma deal

...Galderma granted Bioventus U.S. rights to commercialize Durolane for pain associated with knee osteoarthritis. Bioventus said...
...to disclose financial terms. Galderma S.A. , Lausanne, Switzerland Bioventus Inc. , Durham, N.C. Business: Neurology Shannon Lehnbeuter Durolane Bioventus Inc. Galderma...
BioCentury | Aug 15, 2016
Company News

Bioventus sales and marketing update

...WAC) is $345 per 2 mL injection; one treatment comprises three injections of hyaluronic acid. Bioventus Inc....
BioCentury | Aug 8, 2016
Financial News

Bioventus withdraws IPO

...Neurology Date announced: 2016-08-02 Type: IPO Underwriters: JPMorgan; Piper Jaffray; Stifel, Nicolaus; Leerink Partners Note: Bioventus...
BioCentury | Jul 25, 2016
Financial News

Bioventus amends IPO

...million Price: $16-$18 Underwriters: JPMorgan; Piper Jaffray; Stifel, Nicolaus; Leerink Partners Overallotment: 1.3 million Note: Bioventus...
BioCentury | Jul 11, 2016
Financial News

Bioventus proposes IPO

...$150 million Shares: TBD Price: TBD Underwriters: JPMorgan; Piper Jaffray; Stifel, Nicolaus; Leerink Partners Note: Bioventus...
BioCentury | Jul 11, 2016
Finance

Ground up

...To be raised (A) Status (B) AdAlta Ltd. (ASX) 7/8/16 Up to A$10M ($7.4M) Preclin Bioventus Inc....
Items per page:
1 - 10 of 18
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...a CD37-targeted radionuclide therapy to treat lymphoma (see “Radiotherapy Blasts Forward” ). Bone healing company Bioventus Inc....
...Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen Pharma Ltd. Iveric bio Inc. Nordic Nanovector ASA Viracta Therapeutics Inc. Bioventus Inc....
BioCentury | Apr 30, 2019
Distillery Therapeutics

BMP2/BMP6/activin A-based chimera for bone repair

...chimera plus the granule-COL1 matrix increased bone remodeling compared with pretreatment baselines. Next steps by Bioventus Inc....
...repair. TARGET/MARKER/PATHWAY: Bone morphogenetic protein 2 (BMP2); BMP6; activin A LICENSING STATUS: Patented; licensed to Bioventus Inc....
...published online Apr. 24, 2019 doi:10.1126/scitranslmed.aar4953 CONTACT: Howard J. Seeherman, Bioventus Inc., Durham, N.C. email: hseeherman@gmail.com Claire Quang Bioventus Inc. Activin...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...He was CFO and head of business development at AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX). Orthobiologics company Bioventus Inc....
BioCentury | May 2, 2017
Company News

Management tracks

...15. He will succeed Edward Borkowski, who is leaving the company. Price was CFO of Bioventus Inc....
BioCentury | Dec 30, 2016
Company News

Bioventus, Galderma deal

...Galderma granted Bioventus U.S. rights to commercialize Durolane for pain associated with knee osteoarthritis. Bioventus said...
...to disclose financial terms. Galderma S.A. , Lausanne, Switzerland Bioventus Inc. , Durham, N.C. Business: Neurology Shannon Lehnbeuter Durolane Bioventus Inc. Galderma...
BioCentury | Aug 15, 2016
Company News

Bioventus sales and marketing update

...WAC) is $345 per 2 mL injection; one treatment comprises three injections of hyaluronic acid. Bioventus Inc....
BioCentury | Aug 8, 2016
Financial News

Bioventus withdraws IPO

...Neurology Date announced: 2016-08-02 Type: IPO Underwriters: JPMorgan; Piper Jaffray; Stifel, Nicolaus; Leerink Partners Note: Bioventus...
BioCentury | Jul 25, 2016
Financial News

Bioventus amends IPO

...million Price: $16-$18 Underwriters: JPMorgan; Piper Jaffray; Stifel, Nicolaus; Leerink Partners Overallotment: 1.3 million Note: Bioventus...
BioCentury | Jul 11, 2016
Financial News

Bioventus proposes IPO

...$150 million Shares: TBD Price: TBD Underwriters: JPMorgan; Piper Jaffray; Stifel, Nicolaus; Leerink Partners Note: Bioventus...
BioCentury | Jul 11, 2016
Finance

Ground up

...To be raised (A) Status (B) AdAlta Ltd. (ASX) 7/8/16 Up to A$10M ($7.4M) Preclin Bioventus Inc....
Items per page:
1 - 10 of 18